RAD RADIOPHARM THERANOSTICS LTD

Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference

Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference

SYDNEY, May 07, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that members of management will be participating in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City.

To register for one-on-one meetings with management in New York City, interested parties should contact John Perez at .

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain. Learn more at .

Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.

For more information:

Investors:

Riccardo Canevari

CEO & Managing Director

P:

E:

Anne Marie Fields

Precision AQ (formerly Stern IR)

E:

Media:

Matt Wright

NWR Communications

P:

E:

Follow Radiopharm Theranostics:

Website –

X –   

LinkedIn –

InvestorHub – /



EN
07/05/2025

Underlying

RADRADIOPHARM THERANOSTICS LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RADIOPHARM THERANOSTICS LTD

 PRESS RELEASE
Free
RAD RADIOPHARM THER...

Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Stu...

Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01) First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center  Preclinical animal studies of BetaBart (RV-01) have demonstrated tumor shrinkage and prolonged survival SYDNEY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need,...

February 24, 2026 1 EN
 PRESS RELEASE
Free
RAD RADIOPHARM THER...

Radiopharm Theranostics Reports Half-Year Financial Results and Busine...

Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases  Interim data from additional Cohorts of the Phase 1 clinical trial of RAD 202 and RAD 204 in advanced solid tumors are expected in mid-2026 Cash and cash equivalents of approximately $34.52 million provide runway into 2027 to advance pipeline of high value radiotherapeutic programs through key clinical and regulatory milest...

January 28, 2026 1 EN
 PRESS RELEASE
Free
RAD RADIOPHARM THER...

RAD Increases Ownership in Radiopharm Ventures to 87.5%

RAD Increases Ownership in Radiopharm Ventures to 87.5% Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm TheranosticsLeading candidate Betabart, a monoclonal antibody targeting B7H3, has received FDA IND clearance for a Phase I therapeutic trial in multiple solid tumors expected to dose the first patient in Q1 2026 First clinical trial globally targeting B7H3 with a systemic radiopharmaceuticalTwo additional preclinical Radiopharm Ventures’ assets show early positive results with plans to move to final candidate selection in 2026 ...

January 12, 2026 1 EN
 PRESS RELEASE
Free
RAD RADIOPHARM THER...

Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients a...

Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases 92% of evaluable patients at interim analysis treated with RAD 101 achieved concordance¹ with MRI imaging (the primary endpoint) with significant and selective tumor uptake in suspected or recurrent brain metastases Company to host webinar on Tuesday, December 16 at 10:00 am AEDT (Australia) / Monday, December 15 at 6:00 pm EST (U.S.) SYDNEY, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a cl...

December 15, 2025 1 EN
 PRESS RELEASE
Free
RAD RADIOPHARM THER...

Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeu...

Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer RAD 402 is a humanized IgG1 internalized by prostate cells, binding KLK3 with high affinity Tb-161 antitumor activity driven by the dual emission of beta particles and Auger electrons SYDNEY, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced...

November 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch